ReviewAutoimmune diseases2014
Treatment of chronic inflammatory demyelinating polyneuropathy: from molecular bases to practical considerations.
Review in Autoimmune diseases, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Systematic literature review of burden of illness in chronic inflammatory demyelinating polyneuropathy (CIDP).Journal of neurology · 2021Pooled it
- Electrophysiological-based automatic subgroups diagnosis of patients with chronic dysimmune polyneuropathies.Journal of neuroengineering and rehabilitation · 2025Article
- Real-world treatment utilization in adults with chronic inflammatory demyelinating polyneuropathy in the United States.Frontiers in neurology · 2025Article
- A pathophysiological and mechanistic review of chronic inflammatory demyelinating polyradiculoneuropathy therapy.Frontiers in immunology · 2025Review
- Intravenous immunoglobulin preparations attenuate lysolecithin-induced peripheral demyelination in mice and comprise anti-large myelin protein zero antibody.Proceedings of the Japan Academy. Series B, Physical and biological sciences · 2023Article
- Expanding the Role of the Pharmacist: Immunoglobulin Therapy and Disease Management in Neuromuscular Disorders.Journal of pharmacy practice · 2022Review
- Individualizing Therapy in CIDP: A Mini-Review Comparing the Pharmacokinetics of Ig With SCIg and IVIg.Frontiers in neurology · 2021Review
- Pediatric CIDP: Diagnosis and Management. A Single-Center Experience.Frontiers in neurology · 2021Article
- Treatment Patterns and Costs of Chronic Inflammatory Demyelinating Polyneuropathy: A Claims Database Analysis.American health & drug benefits · 2019Article
- FTY720 controls disease severity and attenuates sciatic nerve damage in chronic experimental autoimmune neuritis.Journal of neuroinflammation · 2019Article
- Enhanced Immune Response in Immunodeficient Mice Improves Peripheral Nerve Regeneration Following Axotomy.Frontiers in cellular neuroscience · 2016Article
- Variations of the perforin gene in patients with chronic inflammatory demyelinating polyradiculoneuropathy.Genes and immunityArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic inflammatory demyelinating polyneuropathy (CIDP) is an autoimmune disease of the peripheral nervous system, in which both cellular and humoral immune responses are involved. The disease is clinically heterogeneous with some patients displaying pure motor form and others also showing a variable degree of sensory dysfunction; disease evolution may also differ from patient to patient, since monophasic, progressive, and relapsing forms are reported. Underlying such clinical variability there is probably a broad spectrum of molecular dysfunctions that are and will be the target of therapeutic strategies. In this review we first explore the biological bases of current treatments and subsequently we focus on the practical management that must also take into account pharmacoeconomic issues.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.